Peter Mollee

6.2k citations

180 papers · 2.5k indexed · h-index 25

Impact in

Hematology top 1%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 91
- Multiple Myeloma Research and Treatments 53
- Acute Myeloid Leukemia Research 20
Genetics 48
- Chronic Lymphocytic Leukemia Research 27
- Myeloproliferative Neoplasms: Diagnosis and Treatment 16

Co-authors: Devinder Gill (39 shared papers)Michael Crump (8 shared papers)Jill Tate (10 shared papers)Peter Moore (3 shared papers)Kevin Song (5 shared papers)Paula Marlton (21 shared papers)W. Phillip Law (3 shared papers)Armand Keating (7 shared papers)
Journals: Blood (35 papers)British Journal of Haematology (8 papers)Bone Marrow Transplantation (8 papers)Amyloid (4 papers)Journal of Hospital Infection (3 papers)
Partner nations: Australia New Zealand United States

In The Last Decade

Peter Mollee

165 papers receiving 2.4k citations

Peers

Countries citing papers authored by Peter Mollee

Since Specialization

Citations

This map shows the geographic impact of Peter Mollee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Mollee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Mollee more than expected).

Fields of papers citing papers by Peter Mollee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Mollee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Mollee. The network helps show where Peter Mollee may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Mollee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Mollee Line = papers co-authored together Peter Mollee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 180 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial The Lancet Oncology ·Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond, Peter Mollee, Monica Sender, Petra Reinke, R. Neuhaus, H. Lehmkuhl, Heinz A. Horst, Gilles Salles, Franck Morschhauser, Arnaud Jaccard, Thierry Lamy, Malte Leithäuser, Heiner Zimmermann, Ioannis Anagnostopoulos, Martine Raphaël, Hanno Riess, Sylvain Choquet	2011	252
2	Cardiac Amyloid Imaging with¹⁸F-Florbetaben PET: A Pilot Study Journal of Nuclear Medicine ·W. Phillip Law, William Y.S. Wang, Peter Moore, Peter Mollee, Arnold C.T. Ng	2016	130
3	Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study Journal of Hospital Infection ·Peter Mollee, Mark Jones, Jenny Stackelroth, Rosita Van Kuilenburg, Warren Joubert, J. Faoagali, David Looke, J Harper, Archie C. A. Clements	2011	112
4	Plasma Epstein-Barr Virus (EBV) DNA Is a Biomarker for EBV-Positive Hodgkin's Lymphoma Clinical Cancer Research ·Maher K. Gandhi, Eleanore Lambley, Jacqueline M. Burrows, Ujjwal Dua, Suzanne Elliott, Peter J. Shaw, H. Miles Prince, Max Wolf, Kerrie Clarke, Craig Underhill, Anthony K. Mills, Peter Mollee, Devinder Gill, Paula Marlton, John F. Seymour, Rajiv Khanna	2006	90
5	Autologous stem cell transplant for relapsed and refractory peripheral T‐cell lymphoma: variable outcome according to pathological subtype British Journal of Haematology ·Kevin Song, Peter Mollee, Armand Keating, Michael Crump	2003	78
6	Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome Blood Cancer Journal ·Puay Hoon Tan, Andrew H. Wei, Sridurga Mithraprabhu, Nicholas J. Cummings, Hong Bo Liu, Michelle Perugini, Kate Reed, S Avery, S. Patil, Patricia Walker, Peter Mollee, Andrew Grigg, Richard J. D’Andrea, Anthony E. Dear, Andrew Spencer	2014	77
7	How to diagnose amyloidosis Internal Medicine Journal ·Peter Mollee, Patricia Renaut, David Gottlieb, Hugh J. B. Goodman	2013	71
8	Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases Clinica Chimica Acta ·Jillian R. Tate, Peter Mollee, Goce Dimeski, Andrew C. Carter, Devinder Gill	2006	68
9	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines Amyloid ·Vaishali Sanchorawala, Mario Boccadoro, Morie A. Gertz, Ute Hegenbart, Efstathios Kastritis, Heather Landau, Peter Mollee, Ashutosh Wechalekar, Giovanni Palladini	2021	62
10	Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry Clinical Proteomics ·Peter Mollee, Samuel Boros, Dorothy Loo, Jayde E. Ruelcke, Vanessa Lakis, Kim‐Anh Lê Cao, Patricia Renaut, Michelle M. Hill	2016	60
11	Quantitative serum free light chain assay--analytical issues. PubMed ·Jill Tate, Sheree Bazeley, Stephen M. Sykes, Peter Mollee	2009	55
12	Immunity, Homing and Efficacy of Allogeneic Adoptive Immunotherapy for Posttransplant Lymphoproliferative Disorders American Journal of Transplantation ·Maher K. Gandhi, Gwen Wilkie, Ujjwal Dua, Peter Mollee, Karen Grimmett, Timothy J. Williams, N G Whitaker, Devinder Gill, Dorothy H. Crawford	2007	52
13	CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cellsin vitro Leukemia & lymphoma ·Melinda Burgess, Catherine Cheung, Lynne Chambers, Karunya Jenin Ravindranath, Gunjeet Minhas, Louise Knop, Peter Mollee, Nigel A.J. McMillan, Devinder Gill	2012	49
14	Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand Annals of Clinical Biochemistry International Journal of Laboratory Medicine ·Jillian R. Tate, Grahame Caldwell, James Daly, David Gillis, Margaret A. Jenkins, Sue Jovanovich, Helen Martin, Richard Steele, Louise Wienholt, Peter Mollee	2012	48
15	Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome Bone Marrow Transplantation ·Peter Mollee, Ashutosh Wechalekar, Denise Pereira, Norman Franke, Donna Reece, C Chen, A. Keith Stewart	2003	47
16	Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B‐cell lymphoma* British Journal of Haematology ·Kevin Song, Peter Mollee, Bruce Patterson, William Brien, Michael Crump	2002	36
17	A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse Leukemia & lymphoma ·Steven Lane, Russell Saal, Peter Mollee, Mark Jones, Andrew Grigg, Kerry Taylor, John F. Seymour, Glen Kennedy, Bronwyn Williams, Karen Grimmett, Vanessa Griffiths, Devinder Gill, Matthew Hourigan, Paula Marlton	2008	35
18	Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT Thrombosis and Haemostasis ·Chee Tan, Timothy Brighton, Simon McRae, Ross Baker, Huyen Tran, Peter Mollee, Geoffrey Kershaw, Joanne Joseph, Christopher Ward, Marie‐Christine Morel‐Kopp, (unknown)	2012	31
19	CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia Clinical Cancer Research ·Melinda Burgess, Devinder Gill, Richa Singhania, Catherine Cheung, Lynne Chambers, Brent A. Renyolds, Louise Smith, Peter Mollee, Nicholas A. Saunders, Nigel A.J. McMillan	2013	29
20	Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation. PubMed ·Sara L Hall, Jill Tate, Devinder Gill, Peter Mollee	2009	28

About Peter Mollee

Peter Mollee is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Internal Medicine, having authored 180 papers that have together received 2.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (53 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (36 papers), Lymphoma Diagnosis and Treatment (34 papers), Chronic Lymphocytic Leukemia Research (27 papers), Acute Myeloid Leukemia Research (20 papers), Cancer Treatment and Pharmacology (18 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (16 papers) and Viral-associated cancers and disorders (15 papers). The work is most often cited by research in Hematology (841 citations), Genetics (444 citations), Nephrology (273 citations), Oncology (936 citations) and Pathology and Forensic Medicine (514 citations). Peter Mollee has collaborated with scholars based in Australia, New Zealand and United States. Frequent co-authors include Devinder Gill, Michael Crump, Jill Tate, Peter Moore, Kevin Song, Paula Marlton, W. Phillip Law, Armand Keating, Arnold C.T. Ng and William Y.S. Wang. Their work appears in journals such as Blood, British Journal of Haematology, Bone Marrow Transplantation, Amyloid and Journal of Hospital Infection.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact